Anatomic pathology selected abstracts

written by CAP TODAY
November 10, 2025

November 2025—A HER2-low–focused IHC scoring system was validated by nine breast pathologists using digitized images of HER2 IHC slides. The system demonstrated high performance metrics, including accuracy, sensitivity, and specificity, across two data sets, validating its effectiveness.

Molecular pathology selected abstracts

written by CAP TODAY
November 10, 2025

November 2025—A study of four laboratories' experiences with subclassifying variants of uncertain significance (VUS) found that variants were more likely to be reclassified as benign than pathogenic. The VUS-high subclass had the highest percentage of reclassifications, but represented a smaller proportion of total VUS classifications.

Q&A column

written by CAP TODAY
November 10, 2025

November 2025
Q. Clinicians at my hospital doubt my prolactin results. They report patients with prominent pituitary adenomas who have normal prolactin results. There are other patients who have hyperprolactinemia but no adenoma or galactorrhea. In those patients, the prolactin concentrations remain elevated even after therapy. Can you clarify? Read answer.

Q. Is it necessary for a lab to report a corrected sodium level when the glucose level is really high? Studies show pseudohyponatremia can occur due to hyperglycemia. How common is this, and how do we decide which correction factor to use? Is it possible that this is easily overlooked by providers due to comorbidities in patients? Some references say there is a need to correct glucose for each 100 mg/dL increase above 400 mg/dL. Read answer.

Newsbytes

written by CAP TODAY
November 10, 2025

November 2025—UpToDate, a widely used clinical decision support tool, is facing competition from OpenEvidence, an AI-powered tool that provides more accurate and context-specific answers to complex clinical cases. While UpToDate is adding its own AI capabilities, the optimal source of truth for AI-driven clinical decision support remains uncertain.

Put It on the Board

written by CAP TODAY
November 10, 2025

November 2025—The FDA cleared Roche's Elecsys pTau181 test, a blood-based biomarker for Alzheimer's disease assessment in patients 55 and older. The CAP requested an exception for physician J-1 visa holders, concerned the proposed four-year visa limit could hinder international medical graduates pursuing pathology careers. The Association for Molecular Pathology and CAP published a consensus recommendation for a simplified next-generation sequencing molecular biomarker report template.

Randox Toxicology launches a nitazenes array

written by CAP TODAY
November 10, 2025

Nov. 7, 2025—Randox Toxicology has launched its Nitazenes Array, an immunoassay designed to detect a broad spectrum of nitazene analogues from a single sample.

Qiagen to acquire Parse Biosciences for $225 million

written by CAP TODAY
November 10, 2025

Nov. 6, 2025—Qiagen has entered into a definitive agreement to fully acquire Parse Biosciences, a provider of scalable, instrument-free solutions for single-cell research.

Proscia's Access25 now available on demand

written by CAP TODAY
November 10, 2025

Nov. 5, 2025—Access25, a virtual event that featured live demos of Proscia Aperture, Proscia's latest product offering that surfaces patient insights at the moment of diagnosis, is now available on demand by registering at Proscia.com.

FDA clears QuidelOrtho Vitros hs troponin I

assay

written by CAP TODAY
November 10, 2025

Nov. 4, 2025—The FDA has granted QuidelOrtho Corp. 510(k) clearance for the Vitros hs Troponin I Reagent Pack.

BD enteric bacterial panels get clearance, CE-IVDR certification

written by CAP TODAY
November 10, 2025

Nov. 3, 2025—BD has received FDA 510(k) clearance and CE marking for its Enteric Bacterial Panel and Enteric Bacterial Panel Plus for the BD Cor system.